Linezolid is the first of a new class of antibiotics with a unique mechanism of action against Methicillin-Resistant Staphylococcus Aureus (MRSA). This is a Phase IV, double-blinded, randomized study for patients with hospital acquired pneumonia proven to be caused by MRSA. Patients will be treated with linezolid or vancomycin for a minimum of 7 days and up to a maximum of 14 days. The primary objective of this study is to compare the clinical efficacy of linezolid to vancomycin in treatment of pneumonia due to MRSA.
Official Title
Conditions
Pneumonia
Study Type
Interventional
Study Design
Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Further Details
Study Start
June 2004
Eligibility & Criteria
Criteria:- Hospitalized adults aged 18 years or older – Hospital acquired pneumonia (acquired 48 hours after hospitalization) – Chest X-ray or CT scan consistent with the diagnosis of pneumonia – Subjects with severe neutropenia (<500 cells/mm3) are excluded - Subjects with hypersensitivity to linezolid or vancomycin are excluded
Total Enrolment
1200
Contact Details
Call: 1-734-622-7600 ClinicalTrials.gov@Pfizer.com
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.
Related Articles
Need a health appointment?
Find and book a doctor, dentist, physio and more on Healthengine
Find a practitioner
